Evidence map›Paper›PMID 41973398›Full record

ReviewIndian pediatrics2026

Democratizing the Cure: Indigenous Innovations and the Future of Pediatric Cell and Gene Therapy in India.

Prasad Iyer, Rajat Bhattacharyya, Gaurav Kharya

Abstract readReview
PubMed Publisher
In one paragraph

Review in Indian pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Prasad IyerChildren's Blood and Cancer Centre, KK Women's and Children's Hospital, Singapore, Singapore. drprasad_iyer@yahoo.co.uk.ORCID http://orcid.org/0000-0001-7693-1678
Rajat Bhattacharyya *Pediatric Haematology Oncology and Stem Cell Transplant, Apollo Multi-Speciality Hospital Kolkata, Kolkata, West Bengal, India.ORCID http://orcid.org/0000-0003-2500-9936
Gaurav Kharya *Center for Bone Marrow Transplant and Cellular Therapy, Indraprastha Apollo Hospital, New Delhi, India.ORCID http://orcid.org/0000-0003-2181-1825

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cell and gene therapy (CGT) represents a paradigm shift in the treatment of diseases once regarded incurable. This is particularly true for pediatric cancers and inherited disorders which often have a monogenic basis. While the global landscape of CGT is rapidly evolving with numerous approved products, India faces unique challenges in adopting high-cost, complex therapies. This perspective offers a comprehensive overview of the current status of pediatric CGT in India, emphasizing the urgent need for affordable and indigenous alternatives. We examined the spectrum of conditions for which CGT shows potential for pediatric patients, analyzed significant research and clinical studies from India, and investigated the pipeline of new products and therapies approaching clinical trials. This analysis provides a roadmap for the future of this transformative field in India in light of emerging regulatory and ethical regulations.

Indexed as

Cell- and Tissue-Based TherapyGenetic TherapyChildHumansIndiaBiologicsCell therapyGene therapyHemophiliaSickle cell diseaseThalassemia

Identifiers

PMID41973398

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.